A confirmatory study of CL2020 in patients with ST-elevation myocardial infarction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080224979

Enrollment

Registered

2019-12-10

Start date

2019-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-elevation myocardial infarction

Interventions

investigational material(s) Generic name etc : CL2020 INN of investigational material : - Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients diagnosed ST-elevation myocardial infarction -Patients with cardiac dysfunction in spite of successful reperfusion by PCI

Exclusion criteria

Exclusion criteria: -Patients with any existing or previous malignant tumor -Pregnant or nursing women, or women of child-bearing potential

Design outcomes

Primary

Measure	Time frame
efficacy Left ventricular ejection fraction after infusion of CL2020	—

Secondary

Measure	Time frame
efficacy left ventricular end-systolic volume and left ventricular end-diastolic volume after infusion of CL2020 etc.	—

Countries

Japan

Contacts

Public Contactcall center

Life Science Institute Inc.

lsii.chiken-inq@eppharmaline.co.jp+81-3-6748-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026